The European Community Advisory Board
ECAB was created in 1997. At the time, patient advisory boards only existed on an ad-hoc basis and were convened by the pharmaceutical companies, a major limitation that ECAB successfully overcame by putting forward an innovative model for the patient Community to provide meaningful, independent, and valued input in HIV treatment and prevention research.
EATG, within the remit of the European Community Advisory Board (ECAB), addresses critical scientific questions around HIV drug-development and related co-infections as well as access to treatment in the European region as defined by the World Health Organisation.
ECAB is a high-level scientific platform that brings together civil society, scientific researchers, the pharmaceutical industry and international institutions to address key science and policy issues related to HIV and its main co-infections like hepatitis C or tuberculosis.
ECAB is composed by expert patients and treatment advocates coming from the WHO European region continuously working together to end the epidemic by advancing research on HIV/AIDS, broadening access to treatment, training/mentoring new HIV/AIDS advocates and ensuring that the patient Community is a permanent and highly-recognised voice in the research arena. It is a volunteer, Community-based structure, also collaborating actively with national and regional Community Advisory Boards in Europe and other groups sharing the same philosophy in other
ECAB aims to promote the harmonisation of the best available clinical practices, standards of care and access to the latest and best available therapies and diagnostic tools throughout Europe, with a particular regard to Central and Eastern Europe. ECAB members meet regularly with the pharmaceutical industry and researchers to discuss, under confidentiality, the advances in HIV drug development and related co-infections, and access to treatment in the European region.
ECAB ‘s work includes:
Members of the ECAB meet in Brussels on a regular basis (see ECAB calendar of meetings)
ECAB meetings don't only focus on HIV/AIDS. Thematic ECAB meetings are also organised on important topics such as hepatitis C or tuberculosis as co-infections. The coinfection ECAB meetings discuss clinical development, and expanded use of treatments for people living with HIV who are also infected with extensively drug-resistant and multi drug resistent forms of tuberculosis or hepatistis C.
During the first semester of 2014 two HIV ECAB meetings were held in Brussels (February and April) and on on hepatitis C in June in Lisbon. Another HIV ECAB will take place in Brussels in October and a second hepatitis C ECAB will take place in London in December.
ECAB Steering Committee
Chair : Giulio Maria Corbelli
Scientific Officer : Giorgio Barbareschi
Steering Committee Members :
Alain Volny Anne
Luis Mendao (BoD Liaison)
Andrej Senih (Policy Working Group Liaison)
The ECAB Chair
Giulio Maria Corbelli is the Current ECAB Chair. He has been confirmed during the EATG General Assembly of 2014
How ECAB works
ECAB holds meetings at least 4 times per year for 3 days each. The meeting agenda includes discussions with industry and scientists, lectures by researchers and training sessions.
ECAB members commit to work as group members and on specific tasks they might be assigned to (i. e. company liaison, thematic portfolios, minute taking etc.).
ECAB asks pharmaceutical companies to disclose information of scientific and commercial value as it is available and prior to publication. ECAB receives such information under confidentiality.